ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,754.20
0.15%
Dow Jones
42,381.34
0.49%
US Dollar vs MXN
19.6517
0.15%
Brent Oil
70.775
-0.25%
Bitcoin
65,845.80
1.02%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Ascendis Pharma AS (ASND)

  7. Ascendis Pharma AS (ASND) Noticias

ASND

Ascendis Pharma AS (ASND)

Ascendis Pharma AS
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ASND
FechaHoraFuenteTítuloSímboloCompañía
23/09/202415:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
20/09/202415:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ASNDAscendis Pharma AS
19/09/202419:16GlobeNewswire Inc.Ascendis Pharma A/S Announces Pricing of Public Offering of ADSsNASDAQ:ASNDAscendis Pharma AS
18/09/202415:04GlobeNewswire Inc.Ascendis Pharma A/S Announces Proposed Public Offering of ADSsNASDAQ:ASNDAscendis Pharma AS
18/09/202415:01Edgar (US Regulatory)Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:ASNDAscendis Pharma AS
16/09/202406:00GlobeNewswire Inc.Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to PlaceboNASDAQ:ASNDAscendis Pharma AS
13/09/202407:30GlobeNewswire Inc.Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024NASDAQ:ASNDAscendis Pharma AS
11/09/202416:37GlobeNewswire Inc.Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in AdultsNASDAQ:ASNDAscendis Pharma AS
04/09/202404:50IH Market NewsNvidia Subpoenaed by DOJ, Athira Pharma Shares Plunge 71% After Study Fails, Zscaler Falls 15% Post-EarningsNASDAQ:ASNDAscendis Pharma AS
03/09/202416:14GlobeNewswire Inc.Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding AgreementNASDAQ:ASNDAscendis Pharma AS
03/09/202416:06GlobeNewswire Inc.Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding AgreementNASDAQ:ASNDAscendis Pharma AS
03/09/202416:04GlobeNewswire Inc.Ascendis Pharma Reports Second Quarter 2024 Financial ResultsNASDAQ:ASNDAscendis Pharma AS
28/08/202407:30GlobeNewswire Inc.Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024NASDAQ:ASNDAscendis Pharma AS
13/08/202404:43IH Market NewsDell Stock Slide Offers Opportunities; Trump and Musk hold talks on X; GM Restructures China Operations, and MoreNASDAQ:ASNDAscendis Pharma AS
12/08/202406:00GlobeNewswire Inc.FDA Approves YORVIPATH® (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in AdultsNASDAQ:ASNDAscendis Pharma AS
04/07/202411:49PR Newswire (Canada)Pendopharm signe une entente de distribution exclusive avec Ascendis Pharma A/S pour TransCon MC PTH au CanadaNASDAQ:ASNDAscendis Pharma AS
04/07/202411:48PR Newswire (Canada)Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in CanadaNASDAQ:ASNDAscendis Pharma AS
24/06/202415:45GlobeNewswire Inc.Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024NASDAQ:ASNDAscendis Pharma AS
04/06/202415:01GlobeNewswire Inc.Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:ASNDAscendis Pharma AS
03/06/202415:01GlobeNewswire Inc.Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024NASDAQ:ASNDAscendis Pharma AS
30/05/202407:30GlobeNewswire Inc.Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024NASDAQ:ASNDAscendis Pharma AS
29/05/202415:08Edgar (US Regulatory)Form SD - Specialized disclosure reportNASDAQ:ASNDAscendis Pharma AS
14/05/202413:31GlobeNewswire Inc.Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
13/05/202407:30GlobeNewswire Inc.Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway TrialNASDAQ:ASNDAscendis Pharma AS
09/05/202407:30GlobeNewswire Inc.Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024NASDAQ:ASNDAscendis Pharma AS
02/05/202415:01GlobeNewswire Inc.Ascendis Pharma Reports First Quarter 2024 Financial ResultsNASDAQ:ASNDAscendis Pharma AS
25/04/202415:46GlobeNewswire Inc.Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024NASDAQ:ASNDAscendis Pharma AS
24/04/202407:30GlobeNewswire Inc.United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
07/03/202410:31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
04/03/202407:30GlobeNewswire Inc.Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024NASDAQ:ASNDAscendis Pharma AS
 Showing the most relevant articles for your search:NASDAQ:ASND

Su Consulta Reciente

AMEX
XLV
Health Care Select Sector
COIN
ADAUSD
Cardano
FX
USDMXN
US Dollar vs MXN
NYSE
KO
Coca Cola
NYSE
MCD
McDonalds
COIN
DOGEUSD
Dogecoin
NYSE
DIS
Walt Disney
CCOM
US500
US 500
COIN
XRPUSD
Ripple
AMEX
SPY
SPDR S&P 500
NYSE
BAC
Bank of America
COIN
SOLUSD
Solana
SPI
SP500
S&P 500
NASDAQ
NVDA
NVIDIA
CCOM
SILVER
SILVER
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados